Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2006-12-23 / Breast Cancer Res. Treat. 2007 Nov;105(3):277-86Larger numbers of immature dendritic cells augment an anti-tumor effect against established murine melanoma cells
/in International Publications, Malignant Melanoma /von 2006-12-19 / Biotechnol. Lett. 2007 Mar;29(3):351-7Steady-state and inflammatory dendritic-cell development
/in Dendritic Cells, International Publications /von 2006-12-15 / Nat. Rev. Immunol. 2007 Jan;7(1):19-30Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy
/in Acute Leukemia, International Publications /von 2006-12-01 / J Clin Apher 2006 Dec;21(4):233-40Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with lewis lung carcinoma and B16 melanoma cells
/in International Publications, NSCLC /von 2006-12-01 / Int J Hyperthermia 2006 Dec;22(8):699-712Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
/in Colorectal Cancer, International Publications /von 2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells
/in Colorectal Cancer, International Publications /von 2006-12-01 / Oncol. Rep. 2006 Dec;16(6):1317-24[Dendritic cells and gliomas: a hope in immunotherapy?]
/in Glioblastoma, International Publications /von 2006-12-01 / Neurochirurgie 2006 Dec;52(6):555-70Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism
/in Hyperthermia, International Publications /von 2006-12-01 / Nat. Immunol. 2006 Dec;7(12):1299-308
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de